CR20220213A - Nuevo proceso químico para la elaboración de 6–cloro–4–(4–fluoro–2–metilfenil)piridin–3–amina, un intermediario clave de nt–814 - Google Patents

Nuevo proceso químico para la elaboración de 6–cloro–4–(4–fluoro–2–metilfenil)piridin–3–amina, un intermediario clave de nt–814

Info

Publication number
CR20220213A
CR20220213A CR20220213A CR20220213A CR20220213A CR 20220213 A CR20220213 A CR 20220213A CR 20220213 A CR20220213 A CR 20220213A CR 20220213 A CR20220213 A CR 20220213A CR 20220213 A CR20220213 A CR 20220213A
Authority
CR
Costa Rica
Prior art keywords
methylphenyl
fluoro
pyridin
chloro
amine
Prior art date
Application number
CR20220213A
Other languages
English (en)
Inventor
Marcel Schleusner
Massimo Ghizzoni
Ron Lawrence
Original Assignee
Kandy Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kandy Therapeutics Ltd filed Critical Kandy Therapeutics Ltd
Publication of CR20220213A publication Critical patent/CR20220213A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
    • B01J23/38—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals
    • B01J23/40—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals of the platinum group metals
    • B01J23/44—Palladium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Materials Engineering (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La invención se refiere a un nuevo proceso para la producción de compuesto 2–(3,5–bis(trifluorometil)fenil)–N–(6–cloro–4–(4–fluoro–2–metilfenil)piridin–3–il)–N,2–dimetilpropanamida (Compuesto IX), que es útil en la elaboración de Compuesto 2–[3,5–Bis(trifluorometil)fenil]–N–{4–(4–fluoro–2–metilfenil)–6–[(7S,9aS)–7–(hidroximetil)hexahidropirazino[2,1–c][1,4]oxazin–8(1H)–il]–3–piridinil}–N,2–dimetilpropanamida (Compuesto A).
CR20220213A 2019-11-15 2020-11-09 Nuevo proceso químico para la elaboración de 6–cloro–4–(4–fluoro–2–metilfenil)piridin–3–amina, un intermediario clave de nt–814 CR20220213A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19209562 2019-11-15
PCT/EP2020/081476 WO2021094247A1 (en) 2019-11-15 2020-11-09 New chemical process for making 6-chloro-4-(4-fluoro-2-methylphenyl)pyridin-3-amine a key intermediate of nt-814

Publications (1)

Publication Number Publication Date
CR20220213A true CR20220213A (es) 2022-07-08

Family

ID=68583265

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220213A CR20220213A (es) 2019-11-15 2020-11-09 Nuevo proceso químico para la elaboración de 6–cloro–4–(4–fluoro–2–metilfenil)piridin–3–amina, un intermediario clave de nt–814

Country Status (16)

Country Link
US (1) US20230002322A1 (es)
EP (1) EP4058433A1 (es)
JP (1) JP2023501666A (es)
KR (1) KR20220101090A (es)
CN (1) CN114728906A (es)
AR (1) AR120468A1 (es)
AU (1) AU2020381762A1 (es)
CA (1) CA3161336A1 (es)
CO (1) CO2022006071A2 (es)
CR (1) CR20220213A (es)
IL (1) IL292921A (es)
JO (1) JOP20220111A1 (es)
MX (1) MX2022005867A (es)
PE (1) PE20221167A1 (es)
TW (1) TW202128625A (es)
WO (1) WO2021094247A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019233606A1 (en) 2018-03-14 2020-09-17 KaNDy Therapeutics Limited Novel pharmaceutical formulation comprising dual NK-1/NK-3 receptor antagonists

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0017256D0 (en) 2000-07-13 2000-08-30 Merck Sharp & Dohme Therapeutic agents
TWI259180B (en) 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives
BRPI0412291A (pt) 2003-07-03 2006-09-19 Hoffmann La Roche antagonistas duplos de nka/nk3 para o tratamento de esquizofrenia
US20060030600A1 (en) * 2004-08-06 2006-02-09 Patrick Schnider Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
WO2007028654A1 (en) * 2005-09-09 2007-03-15 Smithkline Beecham Corporation Pyridine derivatives and their use in the treatment of psychotic disorders
MX2012002369A (es) 2009-08-27 2012-03-29 Glaxosmithkline Llc Formas de anhidrato de un derivado de piridina.
US9403772B2 (en) 2011-11-29 2016-08-02 Helsinn Healthcare Sa 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium as a neurokinin receptor modulator
JP5806420B1 (ja) 2013-11-08 2015-11-10 キッセイ薬品工業株式会社 カルボキシメチルピペリジン誘導体
TWI649307B (zh) 2014-05-07 2019-02-01 日商橘生藥品工業股份有限公司 Cyclohexylpyridine derivative
EP3574907B1 (en) 2015-05-18 2023-08-23 KaNDy Therapeutics Limited A dual nk-1/nk-3 receptor antagonist for the treatment of sex-hormone-dependent diseases
AU2019233606A1 (en) 2018-03-14 2020-09-17 KaNDy Therapeutics Limited Novel pharmaceutical formulation comprising dual NK-1/NK-3 receptor antagonists

Also Published As

Publication number Publication date
IL292921A (en) 2022-07-01
CA3161336A1 (en) 2021-05-20
EP4058433A1 (en) 2022-09-21
JOP20220111A1 (ar) 2023-01-30
AR120468A1 (es) 2022-02-16
AU2020381762A1 (en) 2022-06-02
CO2022006071A2 (es) 2022-05-20
MX2022005867A (es) 2022-06-14
CN114728906A (zh) 2022-07-08
WO2021094247A1 (en) 2021-05-20
JP2023501666A (ja) 2023-01-18
TW202128625A (zh) 2021-08-01
KR20220101090A (ko) 2022-07-19
US20230002322A1 (en) 2023-01-05
PE20221167A1 (es) 2022-07-25

Similar Documents

Publication Publication Date Title
NZ594776A (en) Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors
NZ597140A (en) Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives
FI114469B (fi) Kortikotropiinia vapauttavan tekijän antagonisteja
CR20220213A (es) Nuevo proceso químico para la elaboración de 6–cloro–4–(4–fluoro–2–metilfenil)piridin–3–amina, un intermediario clave de nt–814
HRP20110457T1 (hr) Derivati piridina i njihova upotreba u liječenju psihotičnih poremećaja
NZ599040A (en) 2,4-disubstituted pyrido[4,3-d]pyrimidin-5(6h)-one compounds for selective inhibitors of lrrk2 and syk kinases
PE20050348A1 (es) Metanosulfonato del ester etilico del acido 3-[ (2-{ [4-(hexiloxicarbonilamino-imino-metil)-fenilamino]-metil} -1-metil-1h-bencimidazol-5-carbonil)-piridin-2-il-amino] -propionico
NZ618691A (en) Fused benzoxazepinones as ion channel modulators
NZ749437A (en) Processes and intermediates for making a jak inhibitor
PE20170677A1 (es) Nuevos compuestos como inhibidores de reorganizado durante la transfeccion (ret)
PE20140832A1 (es) Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
PE20170004A1 (es) Inhibidores de biaril cinasa
AR078766A1 (es) Formas solidas de n-(4-(7-azabiciclo(2.2.1) heptan-7-il)-2-( trifluorometil) fenil)-4-oxo-5-(trifluorometil)-1,4- dihidroquinolina-3-carboxamida
RS51423B (en) BENZOIMIDAZOL-2-IL PYRIMIDINI I KAO PYRAZID MODULATORS HISTAMINSKOG H4 RECEPTOR
PE20141023A1 (es) Derivados de (1,2,4) triazolo [4,3-a] quinoxalina como inhibidores de fosfodiesterasas
HK1158650A1 (en) Solid forms of n-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2- (trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3- carboxamide n-(4-(7-[221]-7-)-2-())-4--5-()-1 4--3-
PE20130188A1 (es) Pirrolidinonas heteroaromaticas fusionadas como inhibidores de syk
NZ598269A (en) Aryl sulphone derivatives as calcium channel blockers
NZ611151A (en) Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
RU2012114846A (ru) Соединение глицина
PE20120110A1 (es) [1,2,4]triazolo[1,5-a]piridinas como inhibidores de cinasa
PH12020551457A1 (en) Novel pharmaceutical formulation comprising dual nk-1/nk-3 receptor antagonists
WO2008155572A3 (en) Fused quinoline derivatives useful as gaba modulators
MX2019012507A (es) Polimorfos y formas solidas de la (s)-2-((2-((s)-4-(difluorometil) -2-oxooxazolidin-3-il)-5,6-dhidrobenzo[f]midazo[1,2-d] [1,4]oxazepin-9-il)amino)propanamida, y metodos de produccion.
TW200609218A (en) Bicyclic compounds